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Abstract
Background:  Signaling networks promoting cell growth and proliferation are frequently
deregulated in cancer. Tumors often are highly dependent on such signaling pathways and may
become hypersensitive to downregulation of key components within these signaling cascades. The
classical mitogenic cascade transmits stimuli from growth factor receptors via Ras, Raf, MEK and
ERK to the cell nucleus and provides attractive molecular targets for cancer treatment. For
example, Ras and Raf kinase inhibitors are already in a number of ongoing phase II and phase III
clinical trials. In this study the effect of the Raf kinase inhibitor BAY 43-9006 and of the MEK
inhibitor CI-1040 (PD184352) on a Raf dependent lung tumor mouse model was analyzed in detail.
Methods: We have generated a lung cancer mouse model by targeting constitutively active C-Raf
kinase to the lung. These mice develop adenomas within 4 months of life. At this time-point they
received daily intraperitoneal injections of either 100 mg/kg BAY 43-9006 or CI-1040 for additional
21 days. Thereafter, lungs were isolated and the following parameters were analyzed using
histology and immunohistochemistry: overall lung structure, frequency of adenoma foci,
proliferation rate, ERK activity, caspase-3 activation, and lung differentiation.
Results: Both inhibitors were equally effective in vitro using a sensitive Raf/MEK/ERK ELISA. In
vivo, the systemic administration of the MEK inhibitor CI-1040 reduced adenoma formation to a
third and significantly restored lung structure. The proliferation rate of lung cells of mice treated
with CL-1040 was decreased without any obvious effects on differentiation of pneumocytes. In
contrast, the Raf inhibitor BAY 43-9006 did not influence adenoma formation in vivo.
Conclusion: The MEK inhibitor CI-1040 may be used for the treatment of Ras and/or Raf-
dependent human malignancies.
Background
Oncogene-based therapeutics is a novel approach to
inhibit proteins, which are essential for the initiation and
maintenance of malignancies [1]. Agents such as Hercep-
tin for the treatment of advanced breast cancer and
Gleevec for chronic myelogenous leukemia have proven
that cancer therapies targeting specific molecular altera-
tions in signaling pathways are successful [2]. The Ras-
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MAP kinase pathway has a central role in regulating tumor
cell growth and survival, differentiation and angiogenesis
and has been targeted for therapeutic intervention in the
past [3,4]. C-Raf kinase and MEK are downstream effec-
tors of the Ras signaling cascade. Both kinases are essential
for cellular homeostasis and induce both proliferation
and survival by suppression of apoptosis [5]. Raf and Ras
mutations found in human malignancies convey constitu-
tive activity to these signaling molecules thereby convert-
ing them into an oncogenic state [6].
In this study the Raf inhibitor BAY 43-9006 [7] and the
MEK inhibitor CI-1040 [8] were tested as potential drugs
in a transgenic mouse lung cancer model [9]. We have pre-
viously established this mouse model by expressing
mutated, constitutively active C-Raf kinase (C-Raf BxB)
under the control of the human surfactant protein C (SP-
C) promoter [10]. C-Raf BxB lacks the regulatory NH2-ter-
minal sequences including the Ras interaction domain.
Lung targeted expression of constitutively active C-Raf
induced lung adenomas within 4 months of life [10].
Although these adenomas are stable for more than one
year, deficiencies in other genes such as Bcl-2 or p53 were
found to modulate adenoma growth or even switch the
phenotype of tumor cells, respectively [11,12]. The effects
of BAY 43-9006 and CI-1040 were assessed in this lung
adenoma model by daily intraperitoneal injections of
these drugs at concentrations of 100 mg per kg body
weight over a period of three weeks to four months old C-
Raf-BxB mice.
Methods
ELISA
Enzyme-linked immunosorbent assay for the MEK signal-
ing cascade was done as previously described [13]. In
brief, plates were coated with an anti ERK-antibody (Santa
Cruz, sc-94). A kinase reaction was performed in the pres-
ence of ERK, Raf, MEK and the respective inhibitor. Phos-
phorylated ERK was detected by a sandwich technique
using a secondary antibody (BioLabs, #9106L) and a per-
oxidase-linked species-specific tertiary antibody (Amer-
sham Pharmacia Biotech, #NA 931). Similar results were
obtained with constitutively active C-Raf BxB (data not
shown).
Animals
Lung targeted expression of constitutively active C-Raf
(SP-C C-Raf BxB), lacking the regulatory N-terminal
sequences, which comprise the Ras interaction domain,
induced lung adenomas within 4 months of life [10]. The
adenomas were indistinguishable from those induced by
expression of wild type C-Raf (data not shown). Litters of
the transgenic mice were randomly assigned to the control
groups (no treatment, n = 11, respectively placebo treat-
ment, n = 12) and to the study group (BAY 43-9006 or CI-
1040: daily intraperitoneal injections at a dose of 100 mg/
kg from 4 months of age over a period of 21 days, n = 12
each group). At this dose both drugs were well tolerated
(data not shown). Serum concentration of BAY 43-9006
was determined by liquid-liquid extraction and consecu-
tive HPLC analysis [14]. Lungs were isolated and analyzed
at the end of the treatment period. Animals were com-
pared to non-treated or placebo-treated transgenic mice of
the same litter. Placebo treatment did not cause any
changes in comparison to untreated mice (data not
shown).
Histology and immunohistochemistry
Lungs were fixed under 25 cm water pressure with forma-
lin. Histology was done on formalin-fixed, paraffin-
embedded lung specimen. 4 µm-cut sections were depar-
affinized, rehydrated in graded alcohols and hematoxylin
and eosin stained. Antigen retrieval was performed with
citrate buffer, pH 6.0, and microwave treatment. Endog-
enous peroxidase activity was blocked by incubation with
3% methanol. Unspecific binding was blocked by normal
goat serum. The primary antibody for p-ERK (Cell signal-
ing 9101), PCNA (DAKO M 0879), for Ki-67 (DAKO M
7249) and Bmi-1 (Santa Cruz sc-10745) were detected by
a peroxidase labelled secondary antibody (DAKO P0450).
Corresponding secondary antibodies were used to detect
activated caspase-3 primary antibody (Cell signaling
9664) and pro-SP-C antibody (generous gift of Dr. Jeffrey
A. Whitsett, Cincinnati Children's Hospital Medical
Center, OH/USA). Staining was performed using diami-
nobenzidine and hematoxylin counterstaining. Slides
were analyzed in a blinded fashion. Random pictures
were taken of each specimen. Adenoma foci were counted
per mm2. Positive cells in adenoma foci were counted and
expressed as percentage of all adenoma cells.
Results
BAY 43-9006 and CI-1040 are equally effective in vitro but 
differ in their in vivo properties
To determine whether the inhibitors used in our study are
active we performed at first an in vitro assay. The activity
of BAY 43-9006 and CI-1040 was measured using an
ELISA method that detects phosphorylation of ERK that is
dependent on Raf and MEK activity [13]. Both substances
were equally effective in vitro with complete inhibition of
ERK phosphorylation at concentrations of less than 1 µM
(Fig. 1a). The IC50 values for inhibition of C-Raf by BAY
43-9006 and by CI-1040 in our assays were 16 nM and 12
nM, respectively. In addition, the effect of both inhibitors
was also tested on cell lines. At a concentration of 0,01 µM
the inhibitory effect of CI-1040 on ERK phosphorylation
was more than 90 %, whereas BAY 43-9006 at 4 µM lead
to an inhibition in the range between 60 – 80 % as deter-
mined by Western blotting and immunohistochemistry
(data not shown).BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/24
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At next, the in vivo effects of a systemic administration of
the inhibitors were analyzed using our Raf dependent
lung tumor mice. Comparable serum concentrations of
both inhibitors were reached after intraperitoneal injec-
tion as determined by liquid-liquid extraction of mouse
serum and consecutive HPLC analysis [14] and Sirrenberg
unpublished data). Lung sections of transgenic mice that
have been treated for three weeks with either CI-1040 or
BAY 43-9006 were examined for the amount of phospho-
rylated ERK. After treatment with CI-1040 the amount of
phosphorylated ERK was clearly reduced as determined by
immunohistochemistry (Fig. 1b) or Western blotting
(data not shown). The number of cells that were stained
by the Phospho-ERK antibody was reduced almost three-
fold (Fig. 1c). In contrast, phosphorylation of ERK in lung
adenomas in vivo was virtually not affected by systemic
treatment of mice with BAY 43-9006 (Fig. 1b,1c) or in
controls (data not shown). Moreover, treatment with CI-
1040 did not only reduce adenomas but also improve the
overall lung structure with thin alveolar walls, whereas
MEK inhibitor CI-1040 but not Raf inhibitor BAY 43-9006 reduces lung adenomas in vivo Figure 1
MEK inhibitor CI-1040 but not Raf inhibitor BAY 43-9006 reduces lung adenomas in vivo. (A) MEK activity was 
completely inhibited in vitro by BAY 43-9006 and CI-1040 as determined by ERK activation enzyme-linked immunosorbent 
assay. IC50 values for BAY 43-9006 and CI-1040 were 16 nM and 12 nM respectively. (B, C) The amount of P-ERK and the 
number of P-ERK positive cells were reduced in vivo by treatment with CI-1040 but not with BAY 43-9006. (D, E, F) Treat-
ment with CI-1040 but not with BAY 43-9006 reduced adenomas and improved lung structure after 21d (hematoxylin and 
eosin staining; scale bars = 60 µm). Lung adenomas as well as the overall lung morphology was indistinguishable in placebo 
treated and untreated animals (data not shown).
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BAY 43-9006 again has no detectable effect (Fig.
1d,1e,1f).
The number of adenoma foci per mm2 was determined
and found to be reduced more than 75 % after CI-1040
treatment in comparison to BAY 43-9006 treated or pla-
cebo treated animals (Fig. 2a). This treatment results in a
reduced ratio of lung to body weight of lungs obtained
from mice after CI-1040 treatment (7.5 ± 0.3 mg/g) in
comparison to lungs isolated from mice after BAY 43-
9006 treatment (10.4 ± 0.6 mg/g, P < 0.05).
CI-1040 reduces proliferation in lung adenomas but has no 
influence on apoptosis or lung specific differentiation
The adenoma foci were further analyzed for proliferation,
apoptosis and differentiation to decipher the mechanism
of action by which CI-1040 reduced adenomas. We
assessed proliferation by immunohistochemistry for pro-
liferating cellular antigen (PCNA), Ki-67 and Bmi-1. The
percentage of PCNA positive cells was clearly reduced by
half after CI-1040 treatment (Fig. 2b). The percentage of
Ki-67 and Bmi-1 positive cells was reduced to a third after
treatment with CI-1040 (Fig. 2c,2d). Apoptotic cells were
detected by immunohistochemistry for activated caspase-
3 and no difference was detected after BAY 43-9006 or CI-
1040 treatment (Fig. 2e). Adenoma cells were analyzed
for the expression of pro-SP-C as a marker of alveolar type
II cell differentiation. The percentage of pro-SP-C positive
cells did not change after BAY 43-9006 or CI-1040 treat-
ment (Fig. 2f).
Discussion
We were able to show inhibition of ERK phosphorylation
in vitro by both, the MEK inhibitor CI-1040 and the Raf
inhibitor BAY 43-9600. In addition, both drugs inhibited
ERK phosphorylation to a comparable level when tested
on cell lines in tissue culture (data not shown). Although
both inhibitors reached comparable serum concentra-
tions after intraperitoneal administration (data not
shown), the MEK inhibitor was active in mice whereas the
Raf inhibitor was not. Why BAY 43-9006 is not active in
our Raf dependent lung tumor mouse model and whether
Raf and MEK might fulfill different functional roles with
respect to lung adenoma formation needs to be further
addressed in detail in future.
One possible explanation for the observed effects may
relate to differences in the in vivo accessibility of these
inhibitors to sub-cellular sites where C-Raf is localized.
Alternatively, inhibition of Raf kinases might be more dif-
ficult to achieve due to multiple feedback mechanisms
[15], whereas the regulation of MEK is less complex and
inhibition of MEK is easier achieved in the living organ-
ism. Along this line it was already discussed previously
that inhibitors targeting the kinase activity of Raf might
not be useful as anticancer drugs because inhibition of Raf
is always counterbalanced by reactivation [16]. Finally, it
was recently suggested that C-Raf has signaling properties
that are independent of its protein kinase activity [17].
Therefore, it has also to be considered that BAY 43-9006-
bound kinase-inactive C-Raf has still transforming activity
in pneumocyte type II cells. But this possibility appears
unlikely in the light of earlier results demonstrating the
loss of transforming activity and concomitant gain of
dominant-negative function of c-Raf genes with muta-
tions that inactivate the protein kinase activity of C-Raf
[18-20]. Moreover, there is a direct correlation between
reversal of a transformed phenotype by BAY43-9006 and
Phospho-ERK suppression (Sirrenberg and Rapp, unpub-
lished data).
Previous work on CI-1040 has already established that
this drug has a cytostatic effect on subcutaneously
implanted colon tumors of human and mouse origin har-
boring RAS mutations [21]. In addition, in a mouse
model of metastatic melanoma that was dependent on a
B-Raf mutation CI-1040 was preventing the formation of
new pulmonary metastases and caused rapid regression of
already established pulmonary metastases [22]. Both pub-
lications as well as our report indicate that CI-1040 has a
broad spectrum of antitumor activity and will be useful
for the treatment of cancers that are dependent on muta-
tions or overexpression of members of the mitogenic cas-
cade upstream of ERK.
We also determined the effects of both inhibitors on
expression of Bmi-1. The number of Bmi-1 positive cells
in lung sections was reduced more than twofold by CI-
1040, whereas BAY 43-9006 had no effect. The observed
effects of CI-1040 may be limited to proliferation as nei-
ther apoptosis nor alveolar differentiation was directly
affected. Bmi-1 was originally cloned as c-Myc cooperat-
ing oncogene in murine lymphomas [23,24]. A role for
Bmi-1 in human tumorigenesis was recently suggested by
the discovery of Bmi-1 amplification in mantle cell lym-
phomas [25] and of Bmi-1 overexpression in a variety of
tumors including non-small cell lung cancer [26]. Since
CI-1040 might be more effective in inhibiting the prolif-
eration of Bmi-1 positive adenoma cells, we want to
address in future whether Bmi-1 is a self-renewal factor of
lung stem cells or lung adenoma stem cells.
Conclusions
These experiments demonstrate an essential role of MEK/
ERK signaling for the maintenance of Raf induced trans-
formation in vivo. Effects on the ERK pathway in vivo may
be predictive for effective tumor drug design and therapy
of Raf driven tumors. CI-1040 is currently evaluated in
phase II trials and may be a promising anti-proliferative
drug for Ras and/or Raf-dependent human malignancies.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/24
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MEK inhibitor CI-1040 reduces proliferation in lung adenomas but has no influence on apoptosis or lung specific differentiation Figure 2
MEK inhibitor CI-1040 reduces proliferation in lung adenomas but has no influence on apoptosis or lung spe-
cific differentiation. (A) The number of adenoma foci per mm2 was reduced after treatment with CI-1040 but not with BAY 
43-9006. (B) CI-1040 reduced the PCNA positive cells in lung adenomas by half but not BAY 43-9006. (C, D) Ki-67 and Bmi-1 
positive cells were reduced to a third in lung adenomas after CI-1040 treatment. (E) Neither BAY 43-9006 nor CI-1040 acti-
vated the caspase-3 mediated apoptotic pathway in lung adenomas. (F) BAY 43-9006 or CI-1040 treatment did not change cell 
differentiation in lung adenomas, which was assessed by expression of pro-SP-C, a marker for alveolar type II cells.
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